- Home
- ITRG vs ALT Comparison
ITRG vs ALT Comparison
Compare ITRG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | ALT |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.2M | 573.8M |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ITRG | ALT |
|---|---|---|
| Price | $2.71 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.13 | ★ $17.67 |
| AVG Volume (30 Days) | 2.2M | ★ 3.7M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $67.34 | N/A |
| Revenue Next Year | $25.89 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $1.99 | $2.56 |
| 52 Week High | $4.87 | $6.44 |
Technical Indicators
Market Signals| Indicator | ITRG | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 53.77 |
| Support Level | $2.64 | $3.18 |
| Resistance Level | $2.80 | $3.32 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 37.14 | 39.63 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.